Table 3.
Potential Predictors and Pharmacodynamic Markers of Response to HGF-cMET Axis Inhibitors
| Author | Marker | Disease | Treatment | End Point |
|---|---|---|---|---|
| Eng et al65 | cMET overexpression | Colorectal cancer (KRASwild type) | Panitumuab/rilotumumab | RR |
| Spigel et al,67 Yu et al91 | cMET overexpression | NSCLC | Erlotinib/onartuzumab | PFS and OS |
| cMET amplification | OS (trend) | |||
| Low HGF levels | OS | |||
| Sequist et al68 | Nonsquamous histology | NSCLC | Erlotinib/tivantinib | PFS and OS |
| KRAS mutations | ||||
| EGFR wild type | ||||
| cMET amplification | ||||
| Jhawer et al92 | cMET amplification | Gastric cancer | Foretinib | RR |
Abbreviations: HGF, hepatocyte growth factor; NSCLC, non–small-cell lung cancer; OS, overall survival; PFS, progression-free survival; RR, response rate.